Relmada Therapeutics, Inc. Share Price & Technical Analysis
RLMD · $7.04 (-2.36%)
Healthcare / Biotechnology
$7.04
-2.36%
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-8% return in May, 54% avg return in past 3 year May month.
56% return in 2026, 113% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -29% | 31% | 56% | 6% | -8% | – | – | – | – | – | – | – | 56% |
| 25 | -40% | 0% | 0% | 0% | 167% | -14% | 0% | 83% | 82% | 15% | 105% | 7% | 404% |
| 24 | -7% | 39% | -24% | -23% | -17% | 0% | 23% | -24% | 14% | 9% | -14% | -83% | -108% |
| 23 | 17% | -12% | -36% | 9% | 12% | -14% | 4% | 31% | -14% | 0% | -17% | 64% | 44% |
| 22 | -20% | 11% | 32% | -7% | -25% | 1% | 35% | 15% | 28% | -83% | -25% | -26% | -64% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Neutral
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$752.06M
P/E ratio
—
52W high
$8.00
52W low
$0.52
Volume
6,68,681
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Relmada Therapeutics, Inc. share price today?
- Relmada Therapeutics, Inc. (RLMD) last traded around $7.04 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RLMD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RLMD. Download the app for real-time alerts.
- How can I analyze Relmada Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.